title: Association of seropositivity to Helicobacter species and biliary tract cancer in the ATBC study.
abstract: Helicobacter have been detected in human bile and hepatobiliary tissue. Despite evidence that Helicobacter species promote gallstone formation and hepatobiliary tumors in laboratory studies, it remains unclear whether Helicobacter species contribute to these cancers in humans. We used a multiplex panel to assess whether seropositivity to 15 Helicobacter pylori proteins was associated with subsequent incidence of hepatobiliary cancers in the Finnish Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. We included 64 biliary cancers, 122 liver cancers, and 224 age-matched controls which occurred over the course of 22 years. Helicobacter pylori seropositivity was defined as those positive to ≥ 4 antigens. Odds ratios (OR) and 95% confidence intervals were adjusted for major hepatobiliary cancer risk factors. Among the controls, 88% were seropositive to H. pylori at baseline. Among those who subsequently developed hepatobiliary cancer, the prevalence of seropositivity was higher: 100% for gallbladder cancer, 97% of extrahepatic bile duct cancer, 91% of ampula of Vater cancer, 96% of intrahepatic bile duct cancer, and 94% of hepatocellular carcinoma. Although the OR for gallbladder cancer could not be calculated, the OR for the other sites were 7.01 (95% confidence interval [CI]: 0.79-62.33), 2.21 (0.19-25.52), 10.67 (0.76-150.08), and 1.20 (0.42-3.45), respectively, with an OR of 5.47 (95% CI: 1.17-25.65) observed for the biliary tract cancers combined. ORs above 1 were observed for many of the investigated antigens, although most of these associations were not statistically significant.
  
  
  CONCLUSIONS
  Seropositivity to H. pylori proteins was associated with an increased risk of biliary tract cancers in ATBC. Further studies are needed to confirm our findings and to determine how H. pylori might influence the risk of biliary tract cancer.
authors.affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Gwen
authors.initials: G
authors.lastname: Murphy
authors.forename: Angelika
authors.initials: A
authors.lastname: Michel
authors.forename: Philip R
authors.initials: PR
authors.lastname: Taylor
authors.forename: Demetrius
authors.initials: D
authors.lastname: Albanes
authors.forename: Stephanie J
authors.initials: SJ
authors.lastname: Weinstein
authors.forename: Jarmo
authors.initials: J
authors.lastname: Virtamo
authors.forename: Dominick
authors.initials: D
authors.lastname: Parisi
authors.forename: Kirk
authors.initials: K
authors.lastname: Snyder
authors.forename: Julia
authors.initials: J
authors.lastname: Butt
authors.forename: Katherine A
authors.initials: KA
authors.lastname: McGlynn
authors.forename: Jill
authors.initials: J
authors.lastname: Koshiol
authors.forename: Michael
authors.initials: M
authors.lastname: Pawlita
authors.forename: Gabriel Y
authors.initials: GY
authors.lastname: Lai
authors.forename: Christian C
authors.initials: CC
authors.lastname: Abnet
authors.forename: Sanford M
authors.initials: SM
authors.lastname: Dawsey
authors.forename: Neal D
authors.initials: ND
authors.lastname: Freedman
mesh_terms: D001661:Biliary Tract Neoplasms / Q000382:microbiology* / Q000517:prevention & control; D006528:Carcinoma, Hepatocellular / Q000382:microbiology* / Q000517:prevention & control; D016022:Case-Control Studies; D016481:Helicobacter Infections / Q000150:complications*; D006801:Humans; D008113:Liver Neoplasms / Q000382:microbiology* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D014815:Vitamins / Q000627:therapeutic use; D024502:alpha-Tocopherol / Q000627:therapeutic use; D019207:beta Carotene / Q000627:therapeutic use
chemical_list: D014815:Vitamins; D019207:beta Carotene; D024502:alpha-Tocopherol